Ad is loading...
ARCT
Price
$18.34
Change
+$0.83 (+4.74%)
Updated
Nov 29 closing price
PGEN
Price
$0.93
Change
+$0.02 (+2.20%)
Updated
Nov 29 closing price
86 days until earnings call
Ad is loading...

ARCT vs PGEN

Header iconARCT vs PGEN Comparison
Open Charts ARCT vs PGENBanner chart's image
Arcturus Therapeutics Holdings
Price$18.34
Change+$0.83 (+4.74%)
Volume$201.91K
CapitalizationN/A
Precigen
Price$0.93
Change+$0.02 (+2.20%)
Volume$382.86K
CapitalizationN/A
ARCT vs PGEN Comparison Chart
Loading...
ARCT
Daily Signalchanged days ago
Gain/Loss if shorted
Show more...
PGEN
Daily Signalchanged days ago
Gain/Loss if shorted
Show more...
View a ticker or compare two or three
VS
ARCT vs. PGEN commentary
Dec 02, 2024

To compare these two companies we present long-term analysis, their fundamental ratings and make comparative short-term technical analysis which are presented below. The conclusion is ARCT is a Hold and PGEN is a Hold.

COMPARISON
Comparison
Dec 02, 2024
Stock price -- (ARCT: $18.34 vs. PGEN: $0.93)
Brand notoriety: ARCT and PGEN are both not notable
Both companies represent the Biotechnology industry
Current volume relative to the 65-day Moving Average: ARCT: 52% vs. PGEN: 50%
Market capitalization -- ARCT: $496.78M vs. PGEN: $272.98M
ARCT [@Biotechnology] is valued at $496.78M. PGEN’s [@Biotechnology] market capitalization is $272.98M. The market cap for tickers in the [@Biotechnology] industry ranges from $476.43B to $0. The average market capitalization across the [@Biotechnology] industry is $2.7B.

Long-Term Analysis

It is best to consider a long-term outlook for a ticker by using Fundamental Analysis (FA) ratings. The rating of 1 to 100, where 1 is best and 100 is worst, is divided into thirds. The first third (a green rating of 1-33) indicates that the ticker is undervalued; the second third (a grey number between 34 and 66) means that the ticker is valued fairly; and the last third (red number of 67 to 100) reflects that the ticker is undervalued. We use an FA Score to show how many ratings show the ticker to be undervalued (green) or overvalued (red).

ARCT’s FA Score shows that 0 FA rating(s) are green whilePGEN’s FA Score has 0 green FA rating(s).

  • ARCT’s FA Score: 0 green, 5 red.
  • PGEN’s FA Score: 0 green, 5 red.
According to our system of comparison, ARCT is a better buy in the long-term than PGEN.

Short-Term Analysis

It is best to consider a short-term outlook for a ticker by using Technical Analysis (TA) indicators. We use Odds of Success as the percentage of outcomes which confirm successful trade signals in the past.

If the Odds of Success (the likelihood of the continuation of a trend) for each indicator are greater than 50%, then the generated signal is confirmed. A green percentage from 90% to 51% indicates that the ticker is in a bullish trend. A red percentage from 90% - 51% indicates that the ticker is in a bearish trend. All grey percentages are below 50% and are considered not to confirm the trend signal.

ARCT’s TA Score shows that 6 TA indicator(s) are bullish while PGEN’s TA Score has 6 bullish TA indicator(s).

  • ARCT’s TA Score: 6 bullish, 2 bearish.
  • PGEN’s TA Score: 6 bullish, 3 bearish.
According to our system of comparison, ARCT is a better buy in the short-term than PGEN.

Price Growth

ARCT (@Biotechnology) experienced а +8.46% price change this week, while PGEN (@Biotechnology) price change was +3.27% for the same time period.

The average weekly price growth across all stocks in the @Biotechnology industry was +6.34%. For the same industry, the average monthly price growth was +2.50%, and the average quarterly price growth was +11.52%.

Reported Earning Dates

ARCT is expected to report earnings on Nov 07, 2024.

PGEN is expected to report earnings on Feb 26, 2025.

Industries' Descriptions

@Biotechnology (+6.34% weekly)

Biotechnology involves genetic or protein engineering to produce medicines/therapies for treating and preventing ailments. The industry also provides crucial ingredients for diagnostics. This multi-billion-dollar industry is heavily focused on research and development, as companies attempt to continually come up with cutting-edge solutions for health. New discoveries for the treatment of diseases provide opportunities for growth for a company in this industry. Discoveries, however, must pass the regulatory approval from the U.S. Food and Drug Administration (FDA) before they can make it to markets. Amgen Inc., Gilead Sciences, Inc. and Celgene Corporation are examples of companies in this industry.

SUMMARIES
Loading...
FUNDAMENTALS
Fundamentals
ARCT($497M) has a higher market cap than PGEN($273M). PGEN YTD gains are higher at: -30.440 vs. ARCT (-41.833). ARCT has higher annual earnings (EBITDA): -25.93M vs. PGEN (-136.11M). ARCT has more cash in the bank: 237M vs. PGEN (28.6M). PGEN has less debt than ARCT: PGEN (5.75M) vs ARCT (29.4M). ARCT has higher revenues than PGEN: ARCT (142M) vs PGEN (3.96M).
ARCTPGENARCT / PGEN
Capitalization497M273M182%
EBITDA-25.93M-136.11M19%
Gain YTD-41.833-30.440137%
P/E RatioN/AN/A-
Revenue142M3.96M3,583%
Total Cash237M28.6M829%
Total Debt29.4M5.75M511%
FUNDAMENTALS RATINGS
ARCT vs PGEN: Fundamental Ratings
ARCT
PGEN
OUTLOOK RATING
1..100
5050
VALUATION
overvalued / fair valued / undervalued
1..100
48
Fair valued
57
Fair valued
PROFIT vs RISK RATING
1..100
90100
SMR RATING
1..100
9498
PRICE GROWTH RATING
1..100
8261
P/E GROWTH RATING
1..100
100100
SEASONALITY SCORE
1..100
n/a50

Tickeron ratings are formulated such that a rating of 1 designates the most successful stocks in a given industry, while a rating of 100 points to the least successful stocks for that industry.

ARCT's Valuation (48) in the Pharmaceuticals Major industry is in the same range as PGEN (57) in the null industry. This means that ARCT’s stock grew similarly to PGEN’s over the last 12 months.

ARCT's Profit vs Risk Rating (90) in the Pharmaceuticals Major industry is in the same range as PGEN (100) in the null industry. This means that ARCT’s stock grew similarly to PGEN’s over the last 12 months.

ARCT's SMR Rating (94) in the Pharmaceuticals Major industry is in the same range as PGEN (98) in the null industry. This means that ARCT’s stock grew similarly to PGEN’s over the last 12 months.

PGEN's Price Growth Rating (61) in the null industry is in the same range as ARCT (82) in the Pharmaceuticals Major industry. This means that PGEN’s stock grew similarly to ARCT’s over the last 12 months.

PGEN's P/E Growth Rating (100) in the null industry is in the same range as ARCT (100) in the Pharmaceuticals Major industry. This means that PGEN’s stock grew similarly to ARCT’s over the last 12 months.

TECHNICAL ANALYSIS
Technical Analysis
ARCTPGEN
RSI
ODDS (%)
Bullish Trend 3 days ago
90%
Bearish Trend 3 days ago
90%
Stochastic
ODDS (%)
Bullish Trend 3 days ago
80%
Bullish Trend 3 days ago
86%
Momentum
ODDS (%)
Bullish Trend 3 days ago
87%
Bullish Trend 3 days ago
89%
MACD
ODDS (%)
Bullish Trend 3 days ago
85%
Bullish Trend 3 days ago
78%
TrendWeek
ODDS (%)
Bullish Trend 3 days ago
85%
Bullish Trend 3 days ago
85%
TrendMonth
ODDS (%)
Bearish Trend 3 days ago
84%
Bullish Trend 3 days ago
84%
Advances
ODDS (%)
Bullish Trend 3 days ago
83%
Bullish Trend 3 days ago
83%
Declines
ODDS (%)
Bearish Trend 17 days ago
84%
Bearish Trend 14 days ago
86%
BollingerBands
ODDS (%)
Bullish Trend 3 days ago
83%
Bullish Trend 3 days ago
86%
Aroon
ODDS (%)
Bearish Trend 3 days ago
84%
Bearish Trend 3 days ago
90%
View a ticker or compare two or three
Ad is loading...
ARCT
Daily Signalchanged days ago
Gain/Loss if shorted
Show more...
PGEN
Daily Signalchanged days ago
Gain/Loss if shorted
Show more...
Interesting Tickers
1D
1W
1M
1Q
6M
1Y
5Y
1 Day
MFs / NAMEPrice $Chg $Chg %
FDGFX40.120.25
+0.63%
Fidelity Dividend Growth
MNOSX33.510.20
+0.60%
Manning & Napier Overseas Series S
RYSPX92.420.52
+0.57%
Rydex S&P 500 H
ARSKX76.460.37
+0.49%
Archer Stock
FACVX37.780.10
+0.27%
Fidelity Advisor Convertible Secs A

ARCT and

Correlation & Price change

A.I.dvisor indicates that over the last year, ARCT has been loosely correlated with ABCL. These tickers have moved in lockstep 49% of the time. This A.I.-generated data suggests there is some statistical probability that if ARCT jumps, then ABCL could also see price increases.

1D
1W
1M
1Q
6M
1Y
5Y
Ticker /
NAME
Correlation
To ARCT
1D Price
Change %
ARCT100%
+4.74%
ABCL - ARCT
49%
Loosely correlated
+0.33%
AXON - ARCT
49%
Loosely correlated
+1.89%
BMEA - ARCT
46%
Loosely correlated
+3.13%
PGEN - ARCT
45%
Loosely correlated
+2.50%
BEAM - ARCT
44%
Loosely correlated
+0.63%
More